Abstract
Questions:
Should RSV vaccination be recommended in all adults aged ≥75 years?
Should RSV vaccination be recommended in adults aged 60-74 years at increased risk of severe RSV disease?
Populations: Persons aged ≥75 years and persons aged 60-74 years at increased risk of severe RSV disease
Intervention: RSV Protein Subunit Vaccine (GSK Arexvy or Pfizer Abrysvo)
Comparison: No RSV vaccine
Outcomes:
- Respiratory Syncytial Virus (RSV) lower respiratory tract illness/disease (LRTI/LRTD)
- Medically attended RSV LRTI/LRTD
- Hospitalization for RSV respiratory illness
- Severe RSV respiratory illness requiring supplemental oxygen or other respiratory support
- Death due to RSV respiratory illness
- Serious Adverse Events (SAEs)
- Inflammatory neurologic events (e.g., Guillain-Barré syndrome)
- Reactogenicity (grade ≥3)
- Background paper
- Americas
- United States of America
- EtR framework
- RSV (Respiratory syncytial virus)
